76 related articles for article (PubMed ID: 12125626)
1. Anti-HIV agents. TXU-PAP--early results.
TreatmentUpdate; 2000 Feb; 12(1):2. PubMed ID: 12125626
[No Abstract] [Full Text] [Related]
2. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus.
Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL
J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855
[TBL] [Abstract][Full Text] [Related]
3. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.
Uckun FM; Chelstrom LM; Tuel-Ahlgren L; Dibirdik I; Irvin JD; Langlie MC; Myers DE
Antimicrob Agents Chemother; 1998 Feb; 42(2):383-8. PubMed ID: 9527790
[TBL] [Abstract][Full Text] [Related]
4. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV agents. A warning about high viral loads.
TreatmentUpdate; 2003; 15(7):1-2. PubMed ID: 17216865
[No Abstract] [Full Text] [Related]
6. Antiretroviral rounds. CD4 count 423, viral load 12,000: time to treat anyway?
Hodder S; Frank I
AIDS Clin Care; 2006 Jun; 18(6):59-60. PubMed ID: 16791955
[No Abstract] [Full Text] [Related]
7. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
8. Anti-HIV agents. Alternating regimens look promising.
TreatmentUpdate; 2003; 15(5):2-3. PubMed ID: 17216855
[No Abstract] [Full Text] [Related]
9. Anti-HIV agents. How long will a first regimen last?
TreatmentUpdate; 2003; 15(5):1-2. PubMed ID: 17219614
[No Abstract] [Full Text] [Related]
10. [Clinical study on treatment of HIV infected persons based on viral load detection and CD4+ T lymphocyte counting].
Lin X; Xu L; Feng Y; Li J; Pei L; Shen T; Shao Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):211-4. PubMed ID: 12665921
[TBL] [Abstract][Full Text] [Related]
11. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV agents. Is FOTO a treatment interruption that works?
TreatmentUpdate; 2005; 17(5):10-1. PubMed ID: 17219661
[No Abstract] [Full Text] [Related]
13. Complications & side effects. Can statins be used as anti-HIV drugs?
TreatmentUpdate; 2004; 16(7):9. PubMed ID: 17219689
[No Abstract] [Full Text] [Related]
14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
15. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
[TBL] [Abstract][Full Text] [Related]
16. Therapy for early HIV infection: how far back should the pendulum swing?
Schechter M
J Infect Dis; 2004 Sep; 190(6):1043-5. PubMed ID: 15319851
[No Abstract] [Full Text] [Related]
17. Anti-HIV agents. Can valproic acid help flush HIV from hiding?
TreatmentUpdate; 2005; 17(6):4-5. PubMed ID: 17228475
[No Abstract] [Full Text] [Related]
18. Antiretroviral suppression of HIV in the context of persistently low CD4 counts: new insights.
Laurence J
AIDS Read; 2007 Jan; 17(1):7, 18. PubMed ID: 17274141
[No Abstract] [Full Text] [Related]
19. Anti-HIV agents. Receptor blocker (SCH 532706) enters clinical trials.
TreatmentUpdate; 2008 Mar; 20(2):8-9. PubMed ID: 18663778
[No Abstract] [Full Text] [Related]
20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
